The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes. by Witte, T.J.M. de et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/49793
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
| 750 | haematologica/the hematology journal | 2006; 91(6)
Theo de Witte
Ronald Brand
Anja van Biezen
Michel Delforge
Harold Biersack
Reuven Or
Giovanna Meloni
Beppe Bandini
Jorge Sierra
Nicolaus Kröger
Alois Gratwohl
Dietger Niederwieser
for the MDS subcommittee
of the EBMT Chronic Leukemia
Working Party
The role of stem cell source in autologous
hematopoietic stem cell transplantation for patients
with myelodysplastic syndromes
The natural history of myelodysplasticsyndromes (MDS) is variable anddepends on the stage of the disease.1,2
The prognosis of patients with advanced
stages of MDS, therapy-related MDS, or sec-
ondary acute myeloblastic leukemia (AML) is
generally poor with median survivals of less
than 12 months. Various classification sys-
tems have been used to predict the outcome
of MDS patients.3 For young patients with
high-risk MDS allogeneic stem cell transplan-
tation is a curative option. However, an HLA-
identical sibling is only available for one-third
of patients. Disease-free survival after allo-
geneic stem cell transplantation ranges
between 35-45%.4-11 Intensive chemotherapy
with AML-like schedules followed by autolo-
gous stem cell transplantation may provide an
alternative option for patients lacking a suit-
able donor. Intensive chemotherapy results in
complete remission rates of 15-65%.12-16 The
median remission duration without stem cell
transplantation is usually short due to a high
incidence of early relapses. In view of the high
relapse rate after chemotherapy alone trans-
plantation with autologous stem cells after
remission induction and consolidation
chemotherapy has been applied in various
clinical studies.17-19 In 1997 the European
Group for Blood and Marrow Transplantation
(EBMT) reported the results of 79 patients
with MDS, secondary AML or therapy-relat-
ed AML who received an autograft in first
complete remission after chemotherapy. The
2-year survival, disease-free survival and
relapse rates were 39%, 34% and 64%,
respectively.18 Autologous bone marrow (BM)
stem cells for these indications are associated
with prolonged marrow hypoplasia.
Therefore, peripheral blood (PB) has rapidly
replaced BM as the preferred source of stem
cells for autologous hematopoietic stem cell
transplantation (HSCT).20 Early analyses indi-
cated an increased risk of relapse after autolo-
gous PB HSCT, particularly in patients over 40
years old.21
The Chronic Leukemia Registry of the
EBMT contained 432 reports of patients
autografted for MDS or secondary leukemia
in first complete remission. We wanted to
use these data to determine the efficacy of
both stem cell sources for autologous stem
cell transplantation in these patients, by
assessing overall survival, disease-free sur-
vival, transplant-related mortality, and
relapse risk. In addition, we wanted to study
the effects of various prognostic factors, such
as stage and nature of disease, transplant
year, cytogenetic characteristics, and
patients’ age, on the outcome of transplants.
For these reasons we collected additional
information on potential prognostic variables
in this setting, such as year of transplant,
interval between diagnosis and first complete
remission, interval between first complete
remission and transplant, age, type of MDS
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Background and Objectives. Intensive chemotherapy followed by autologous hematopoietic
stem cell transplantation (HSCT) is a curative treatment option for patients with myelodys-
plastic syndromes (MDS). Peripheral blood (PB) HSCT was introduced in 1992 and PB has
become the source of choice of autologous stem cells worldwide. Autologous PB stem cells
result in faster hematopoietic recovery, but may be associated with a higher risk of relapse. 
Design and Methods. We analyzed the data of 336 patients transplanted after 1992 with
either bone marrow (BM) (n=104) or PB (n=232). 
Results. Various factors had an impact on event-free survival in univariate analysis: age (haz-
ard ratio [HR]=1.1 per 10 years; p=0.12), source of stem cells (HR=1.2, p=0.22), interval
between diagnosis and transplantation (HR=1.0 per month; p=0.87), and therapy-related vs
primary disease (HR=0.5; p=0.002). In the multivariate Cox model, the event-free survival
was not different after PB or BM HSCT with a HR of 0.93 (95% confidence interval of 0.67
- 1.30; p=0.67). The relapse risk after transplantation with stem cells from either source
was similar with a HR of 1.1. A significant interaction (p=0.02) between age and the source
of stem cells indicated a more favorable potential of autologous PB HSCT in young age
groups. 
Interpretation and Conclusions. Autologous PB and BM HSCT result in equivalent outcomes.
Therefore, given the more rapid hematopoietic recovery PB is the preferred source of stem
cells. 
Key words: autologous hematopoietic stem cell transplantation, myelodysplastic
syndromes, secondary acute myeloid leukemia, mobilized peripheral blood stem cells,
bone marrow stem cells.
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(therapy-related vs primary MDS or AML-MDS, and
cytogenetics. The main purpose of this analysis was to
test whether the change to PB as the source of stem cells
in this setting has worsened the outcome of HSCT.
Design and Methods
Data were retrieved from the registries of the Chronic
and Acute Leukemia Working Parties of the European
Group for Blood and Marrow Transplantation. These
registries continuously collect data related to patients
transplanted by member teams. Reports were available
for 432 patients transplanted in first complete remis-
sion: 76 with primary MDS, 141 with acute leukemia
secondary to MDS and 79 patients with MDS or sec-
ondary leukemia after cytotoxic therapy for an unrelat-
ed disease. The disease classification was incomplete in
136 patients mainly due a lack of information on prior
cytotoxic therapy in 114 patients with MDS. The medi-
an age of the 432 patients was 49 years (range: 0-73
years) and 198 (46%) were older than 50 years at the
time of transplant. The median interval between diag-
nosis and transplantation was 6 months (range: 1-42
months) for the 76 patients with MDS and 6 months
(range: 1-89 months) for the patients transplanted for
secondary AML or therapy-related MDS/AML.
Cytogenetic data were available for 136 patients.
Patients were stratified according to the International
Prognostic Scoring System (IPSS) cytogenetic classifica-
tion into three risk groups. The source of stem cells was
BM only in 155 patients, 234 patients were treated with
mobilized PB stem cells and 34 patients received stem
cells from both sources. The origin of the stem cells was
not completely clear in 7 patients. None of the stem cell
grafts was subjected to purging procedures. The analy-
sis of this study was restricted to patients transplanted
after 1992 for several reasons: autologous PB HSCT was
introduced in 1992, the average age of patients trans-
planted before 1992 was generally lower, experience
and supportive care may be different in the two periods,
and finally the outcomes of most patients transplanted
before 1992 have already been reported.18
Definitions
MDS and AML were classified according to the crite-
ria of the French-American-British (FAB) working
group.2 AML developing after antecedent myelodyspla-
sia lasting at least 3 months is defined as secondary
AML (or secondary leukemia). MDS or AML occurring
after chemotherapy or radiotherapy is defined as thera-
py-related MDS or therapy-related AML. Complete
remission is defined as a normocellular marrow with
less than 5% blast cells including monocytoid cells and
<10% blast cells + promyelocytes. Peripheral blood
counts should be in the normal range. 
Statistical analysis 
The time intervals for survival, relapse-free survival,
relapse and transplant-related mortality were calculated
from the day of stem cell transplantation onwards. For
the Kaplan-Meier curves (used in univariate descrip-
tions) and Cox models (used to estimate hazard ratios)
the relapsed patients were censored for transplant-relat-
ed mortality at the time of relapse and vice versa. Uni-
variate comparisons of Kaplan-Meier curves were per-
formed using the two-tailed log-rank test. For ordered
categorical variables the trend version of the log-rank
test was used. The association of various risk factors
with the outcomes (overall survival, disease-free sur-
vival, relapse incidence and transplant-related mortality)
was quantified using the hazard ratios estimated in the
Cox models. Actual multivariate estimates for relapse
incidence and transplant-related mortality were made
using  cumulative incidence estimates. The sum of these
two cumulative incidences equals the complement of
the disease-free survival. Calculations were performed
using SPSS version 11. The cumulative incidences were
calculated in NCSS version 2001. 
All models are full models in the sense that no step-
wise backward reduction of models was performed.
Interactions of the main risk factor of interest, the
source of stem cells, with all other covariates were test-
ed in a stepwise backwards manner. For the sake of sim-
plicity interactions with p-values between 0.05 and 0.10
were removed if the hazard ratios among the strata
were pointing in the same direction (i.e. either both
indicating an increased or a decreased risk). The analy-
ses were only carried out on cases for which sufficient
information was available. This meant that two trans-
plants, which had a relevant missing value, were
removed from the analysis. The date of the analysis was
September 26, 2005.
Results
Patients' characteristics
The average age of patients at transplantation was
higher in more recently performed transplantations.
Patients transplanted before 1997 were generally
younger with only 43% of the patients older than 50
years while 56% of the patients transplanted after 1996
were older than 50 years. Seventy-four percent of the
patients over 60 years old were transplanted after 1996.
The average age of patients transplanted with mobi-
lized blood cells was higher than that of patients who
received autologous BM (Table 1). Only eight patients
treated with autologous BM HSCT (8%) were older
than 60 years in contrast to 60 patients (26%) who
received autologous PB HSCT. The interval between
diagnosis and transplantation did not differ according
to the source of stem cells (Table 1). Therapy-related
MDS/AML was not more frequently observed in
patients transplanted with mobilized blood stem cells.
The cytogenetic risk groups were also equally divided
between PB and BM HSCT recipients (Table 1).
Univariate analyses using Kaplan-Meier curves and
log-rank tests
The probability of the 336 patients transplanted in
first complete remission being alive at 3 years was 34%.
The disease-free survival probability was 23%, and the
relapse risk 68% (Table 2). Autologous BM HSCT was
Autologous hematopoietic SCT for MDS
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performed in 104 patients and 232 patients received
autologous PB stem cells. The 3-year disease-free sur-
vival was slightly better after BM than after PB (28%
and 21%, respectively) because of an apparently higher
relapse risk (p=0.07) in the recipients of mobilized PB
stem cells. However, the mean age of BM recipients was
significantly younger (41 years±15 years) than that of
the PB recipients (50 years±14 years). Age had a signifi-
cant impact on the 3-year relapse rate and treatment-
related mortality of the 336 patients autografted in first
complete remission (Table 3). This translated into a
trend (p=0.12) to a lower disease-free survival in the
older age groups (Table 3). After correction for con-
founding factors, such as age, the relapse risk after
autologous PB HSCT was not higher than that after BM
HSCT.
The disease-free survival of patients with therapy-
related MDS/AML was significantly better than that of
the other patients (Table 2). This difference cannot be
explained by a different age distribution in the various
disease categories since the age distribution was not sig-
nificantly different (data not shown). The use of BM and
PB stem cells was similar in all disease categories (data
not shown). The interval between diagnosis and trans-
plantation did not influence the outcome significantly.
Transplantations performed after 1996 resulted in sig-
nificantly lower disease-free survival (20%) compared
to 29% in the earlier period, mainly due to a higher
patient age in the more recent cohort (data not shown).
Multivariate analyses (Cox Model)
The main aim of the multivariate Cox model was to
test the value of transplantation with mobilized PB stem
cells on the various outcomes. This analysis compared
the outcome of autologous PB versus BM HSCT after
having adjusted for age, transplant year, interval diagno-
sis - transplantation and stage/type of MDS at trans-
plantation (primary MDS, AML-MDS vs. therapy-relat-
ed MDS/AML-MDS). Therefore, the interactions of
autologous PB HSCT with all other covariates were
tested in a stepwise backward manner. The disease-free
survival was not different after PB or BM transplanta-
tion with a hazard ratio (HR) of 0.92 and a 95% confi-
dence interval (CI) of 0.67 - 1.30 (p=0.65). The relapse
risk after both forms of autologous HSCT was also
almost identical with a HR of 1.1 (Table 3). An interval
between diagnosis and transplantation of more than 6
months tended to be associated with a better disease-
free survival rate and a significantly lower relapse risk
(Table 4). Age had no impact on disease-free survival
when adjusted for the other variables, but there was a
trend (p=0.2) towards a higher relapse risk in the older
Table 1. Characteristics of 336 patients with myelodysplastic syn-
dromes, secondary acute myeloid leukemia or therapy-related
myelodysplasia/leukemia who received an autologous bone mar-
row (BM) or peripheral blood (PB) stem cell transplantation in first
complete remission after 1992.
BM PB p value
Age (years) 104 232 < 0.001*
0-29 22 (21) 20 (9)
30-39 20 (19) 29 (14)
40-49 26 (25) 46 (20)
50-59 28 (27) 77 (33)
>60 8 (8) 60 (26)
Transplant year < 0.001*
1993-1996 60 (58) 55 (24)
>1996 44 (32) 177 (76)
Interval diagnosis- < 0.04*
Transplantation (months)
< 5 28 (27) 78 (34)
5-8 43 (41) 105 (46)
≥ 8 33 (32) 47 (20)
Disease classification < 0.15°
Primary MDS 24 (23) 41 (17)
Secondary acute leukemias 30 (29) 62 (27)
Therapy-related MDS/AML 21 (20) 35 (15)
MDS unknown history 29 (28) 94 (41)
Cytogenetics (Greenberg) N=136 < 0.11°
Standard 26 (62) 33 (56)
Intermediate 15 (36) 18 (31)
High 1 (2) 8 (13)
*χ2 test for linear-by-linear association (trend test); °χ2 test for association.
Table 2. Three-year disease-free survival (DFS), relapse rate, and
transplant-related mortality (TRM) of 336 patients transplanted in
first complete remission with either autologous bone marrow or
mobilized blood stem cells (univariate calculations).
Number DFS# Relapse$ TRM$
All patients 336 24 61 13
BM HSCT 104 28 56 12
PB HSCT 232 21 64 13
p value 0.22 0.07 0.99
Age
0-29 42 24 57 11
30-39 49 30 53 13
40-49 72 29 64 3
50-59 105 18 66 16
>60 68 16 66 18
p value 0.12 0.02 0.05
Type of MDS
Acute leukemia 
after MDS 92 15 70 13
Primary MDS 65 24 65 6
Therapy-related MDS 56 48 39 12
Unknown 123 14 67 17
p value 0.002 0.005 0.34
Cytogenetics (Greenberg)
Standard 59 31 50 12
Intermediate 33 41 46 9
High 9 56 44 0
Unknown 235 16 69 14
p value 0.32 0.88 0.57
Interval diagnosis-transplantation
≤ 5 months 107 24 63 11
5-8 months 147 27 59 12
> 8 months 80 17 62 15
p value 0.28 0.31 0.56
Transplant year
1993-1996 115 29 57 11
>1996 221 20 63 14
p value 0.04 0.09 0.41
#DFS estimated by the Kaplan-Meier method; $TRM and relapse estimated as
cumalative incidences in a competing risk model; p values: log-rank test
(likelihood-ratio test) from a univariate Cox model. The trend version of the
log-rank test is used when two or more ordered categories  are involved.
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age cohorts (Table 3). Calendar year had an adverse
effect: the HR was around 1.1 (95% CI 1.0-1.2; p=0.03)
denoting an increase in the event rate of 10% per calen-
dar year. Patients with therapy-related MDS/AML may
expect a significantly better event-free survival after
autologous HSCT compared to patients with other
forms of disease, even after adjustment for confounding
factors in the Cox model, including interval between
diagnosis and transplantation (Table 3).
Comparison of autologous BM and PB stem cell
transplantation in various age groups
We observed an age-dependent difference in outcome
in earlier comparisons of autologous BM versus PB
HSCT. Therefore we compared the results of the two
types of HSCT in the various age groups adjusted for
confounding factors such as transplant year, disease cat-
egory, and interval between diagnosis and transplanta-
tion. A significant interaction (p=0.02) between age and
the source of stem cells was detected in this analysis
(Table 4). The HR for disease-free survival between PB
and BM recipients was significantly lower in the
younger age groups than in the older age groups denot-
ing a favorable potential of autologous PB stem cell
transplantation in young age groups. This interaction
can be explained by a significantly lower transplant-
related mortality of PB HSCT carried out at a lower age
when compared with BM HSCT (p=0.04). The same
was true for the relapse risk but this interaction was not
statistically significant (p=0.29). Table 4 shows the esti-
mated hazard ratios and confidence intervals in the var-
ious age groups. 
Table 3. Multivariate analysis for disease-free survival (DFS) and
relapse with main effects only.
Risk factors Categories Hazard 95% Confidence p
for DFS compared ratio interval value
Lower Upper
Source of stem PB (1) 0.7 1.3 0.66
cells BM 0.9
Interval diagnosis <6 months (1) 0.7 1.0 0.08
transplantation ≥6 months 0.8
Age 10 year cohorts 1.0 0.9 1.1 0.66
Calendar year Continuous variable 1.1 1.0 1.2 0.03
AL after MDS (1)
Disease Primary MDS 0.9 0.6 1.3
categories Therapy-related MDS 0.4 0.3 0.7 0.004
MDS with 0.9 0.6 1.2
unknown history
Risk factors Categories Hazard 95% Confidence p
for relapse compared ratio interval value 
Lower Upper
Source of stem cells PB (1) 0.47
BM 1.2 0.8 1.7
Interval 
diagnosis <6 months (1) 0.04
transplantation ≥6 months 0.8 0.6 1.0
Age 10 year cohorts 1.1 1.0 1.2 0.19
Calendar year Continuous variable 1.0 0.9 1.1 0.63
AL after MDS (1)
Disease Primary MDS 0.8 0.5 1.3
categories Therapy-related MDS 0.4 0.3 0.7 0.007
MDS with 1.0 0.7 1.5
unknown history
PB: peripheral blood; BM: bone marrow.
Table 4. Results of a multivariate Cox analysis for disease-free sur-
vival (DFS) relapse and treatment-related mortality (TRM).
Comparison of PB versus BM in various age groups, adjusted for
the interval between diagnosis and transplantation, disease cate-
gories, and transplant year including significant interactions.
Outcome DFS REL TRM
Age HR 95% CI p HR 95% CI p HR 95% CI p
(yrs) value value value
lower upper lower upper lower upper
20 0.5 0.2 0.9 0.02 0.8 0.3 1.8 0.5 0.1 0.02 0.8 0.03
40 0.8 0.6 1.1 0.20 1.1 0.7 1.6 0.8 0.4 0.2 1.0 0.07
60 1.4 0.8 2.3 0.19 1.4 0.8 2.6 0.2 1.5 0.5 4.3 0.5
Disease-free survival: interaction PB/BM *Age: HR=1.3 (95% CI = [1.05-1.7],
p=0.02; the HR of PB versus BM increases by a factor of 1.3 for every 10 years of
patients’ age. Relapse: interaction PB/BM *Age: HR=1.2 (95% CI = [0.9-1.6],
p=0.29; the HR of PB versus BM increases by a factor of 1.2 for every 10 years of
patients’ age. Transplant-related mortality: interaction PB/BM *Age: HR=1.9
(95% CI=[1.0-3.4], p=0.04; the HR of PB versus BM increases by a factor of 1.9
for every 10 years of patients’ age. Model: source of stem cells, year, interval
diagnosis-transplantation, disease type, source. *Age, Year *Age.
Figure 1. Cox model to compare the impact of autologous PB ver-
sus BM HSCT on disease-free survival (DFS) (upper panel) and
relapse risk (lower panel) after adjustment for age, calendar year,
interval diagnosis-transplantation, disease. Hazard ratio (PB vs
BM) for DFS: 0.9 (p=0.66). Hazard Ratio (PB vs BM) for relapse:
1.2 (p=0.47).
Autologous Transplanted MDS/secondary acute leukemia
DFS     Source of Stem Cell
Autologous Transplanted MDS/secondary acute leukemia
Relapse     Source of Stem Cell
0 12 24 36 48 60
0 12 24 36 48 60
p=0.66
1.00
0.80
0.60
0.40
0.20
0.00
1.00
0.80
0.60
0.40
0.20
0.00
p=0.47
PB
PB
BM
BM
Discussion
The experience with autologous transplantation in
high-risk MDS is limited.17-19,22 The EBMT reported a 3-
year survival of 38% for patients transplanted in first
complete remission.22 A French co-operative group
study reported on autologous stem cell transplantation
in 83 patients with MDS.22 Transplantation was per-
formed in 24 of the 39 patients (62%), who achieved
complete remission. The median overall survival was 33
months from transplantation. The hematopoietic recov-
ery after autologous BM stem cell transplantation for
myeloid malignancies is generally slow. Administration
of a high number of stem cells, obtained by mobiliza-
tion of the stem cells into the peripheral blood, may
improve the speed of engraftment. Pilot studies showed
the feasibility of collecting peripheral blood stem cells
from patients in complete remission of MDS.23,24 In a
study in 11 patients in complete remission after
chemotherapy, stem cell mobilization was attempted
either with granulocyte colony-stimulating factor (G-
CSF) alone or with G-CSF after recovery from the con-
solidation course. In seven of these 11 patients sufficient
numbers of cells were harvested, resulting in a CD34
progenitor cell yield >1×106/kg.24 Carella et al. were able
to collect normal progenitor cells from six out of nine
patients who presented with an abnormal karyotype.24
In our own experience stem cell mobilization was feasi-
ble in about 50% of patients in the recovery phase after
chemotherapy with G-CSF.25
Since MDS are clonal hematopoietic stem cell disor-
ders, there remains concern regarding contamination of
the graft by residual malignant cells, especially if high
numbers of mobilized stem cells are used for autologous
HSCT. Several studies have reported that patients with
an abnormal karytotype can achieve a cytogenetic
remission if a morphological remission is reached after
chemotherapy. Delforge et al. reported that polyclonal
immature hematopoietic progenitors can be mobilized
and harvested in patients with high-risk MDS after
treatment with intensive chemotherapy.26 Clonality
analysis was performed in females heterozygous for the
X-linked human androgen-receptor (HUMARA) gene
demonstrating a polyclonal pattern in the CD34+ cell
population in four out of five patients. Murine models
in which no clonal (cytogenetically aberrant) precursors
were identified in NOD/SCID mice transplanted with
marrow from patients with MDS more than 2 months
after transplantation27 support the polyclonal normal
nature of MDS marrow in complete remission after
intensive antileukemic treatment.
The present analysis was performed to assess the
value of autologous PB stem cell transplantation in the
treatment of patients with high-risk MDS. Ideally, this
question should be studied in a prospective setting, but
the number of patients eligible for this treatment
approach is too low to perform such a study within a
reasonable period. Therefore, we performed retrospec-
tive analyses on the data from the EBMT registries to
assess the role of autologous PB HSCT in patients with
MDS. We were confronted with two major confound-
ing factors: a substantial age increase in more recently
performed autotransplantations and a poorer outcome
of autologous BM HSCT recipients whose transplant
was performed before 1992. Therefore we restricted the
analyses to transplants performed after 1992. In addi-
tion we adjusted the outcome for age and other poten-
tially confounding factors. The 3-year disease-free sur-
vival of the 336 patients transplanted in first complete
remission was 24%. The relapse risk of 68% accounted
for the main cause of failure. The 3-year disease-free
survival was slightly better after BM than after PB
HSCT (28% and 21%, respectively), but the mean age
of BM recipients was significantly younger (41 years±15
years) than that of PB recipients (50 years±14 years).
The higher average age may have contributed to the
higher transplant-related mortality and relapse rate after
PB HSCT. The multivariate Cox model adjusted the out-
come of PB versus BM HSCT for age, transplant year,
interval between diagnosis and transplantation and
stage/type of MDS at transplantation (primary MDS,
AML-MDS vs. therapy-related MDS/AML-MDS). The
adjusted disease-free survival and relapse rates were not
different after transplant using the two stem cell
sources. Age had no impact on disease-free survival
when adjusted for the other variables, but there was a
trend (p=0.2) towards a higher risk of relapse in the
older age cohorts probably due to other age-related fac-
tors such as adverse cytogenetic characteristics. When
the impact of age on the two forms of HSCT was ana-
lyzed separately, it appeared that the outcome after PB
HSCT was significantly better in patients younger than
30 years in contrast to the equivalent outcome in older
age groups. The explanation is speculative, but the high-
er incidence of adverse cytogenetic characteristics usu-
ally observed in older MDS patients may have con-
tributed to this effect. In addition, the transplant-related
mortality rate after PB HSCT was significantly lower in
the young age groups, probably reflecting a more rapid
hematopoietic recovery after PB stem cell transplanta-
tion in these young patients. A confusing outcome was
the adverse effect of calendar year. The HR was around
1.1 (p=0.03) denoting an increase in event rate of 10%
per calendar year. However, the mean follow-up time
(among patients still alive) is decreasing steeply and
more than to be expected from 1995 onwards. This may
indicate a selection bias due to mortality overreporting
of recently transplanted patients.
Patients with therapy-related MDS/AML had a signifi-
cantly better disease-free survival than did those with the
other categories of disease, even after adjustment for con-
founding factors in the Cox model, including interval
between diagnosis and transplantation. The explanation
of this unexpected outcome is not straightforward, but
the contribution of  patients with favorable cytogenetic
characteristics might be relevant. We identified eight
patients with t(8;21) or inversion 16 in an incomplete and
ongoing analysis. The 3-year disease-free survival of these
patients was 57% (personal communication N. Kröger). 
Reports in the literature suggest that allogeneic stem
cell transplantation is superior to autologous transplanta-
tion, producing disease-free survival rates varying from
35-45%.4-9,11,28,29  However all these studies have reported
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observational data. Selection of patients fit enough to go
through an allogeneic stem cell transplantation proce-
dure may introduce a selection bias. A multicenter study
by the EORTC, EBMT, the Swiss Group for Clinical
Cancer Research (SAKK) and Gruppo Italiano Malatie
Ematologiche dell'Adulto (GIMEMA) compared the
results of 159 patients who received remission-induction
chemotherapy and were then candidates for allogeneic
and autologous stem cell transplantation depending on
the availability of an HLA-identical sibling.30,31 The per-
centage of patients who received the intended allogene-
ic transplantation (69%) was significantly higher than
the percentage who underwent autologous transplanta-
tion (49%) (p<0.05), as observed for patients with
AML.32,33 The 4-year event-free survival was 23% for
patients with a donor and 22% for patients without a
donor (p=0.66). The results of this EORTC study22 sug-
gest that patients with high-risk MDS and AML-MDS
may benefit from either allogeneic or autologous SCT. 
The results of this study (EORTC 06921) were com-
pared with those of 215 MDS and AML-MDS patients
treated at the MD Anderson Cancer Center.34 The 215
patients in the American study had received various
high-dose cytarabine-containing induction regimens,
and after remission-induction continued to receive these
regimens at reduced dosage for 6-12 months. Remission
rates were 54% and 63%, respectively (p=0.09). Sixty-
five of the EORTC patients who entered complete
remission received a transplant during the first remis-
sion. Disease-free survival in patients achieving com-
plete remission was superior in the EORTC cohort, the
4-year rates being 29% in the EORTC cohort versus
17% in the M.D. Anderson group (p=0.02), but survival
in the two groups was not significantly different. 
A substantial number of patients may not reach the
autologous stem cell transplant procedure because of
failure to achieve remission or failure to produce suffi-
cient numbers of stem cells. Careful clinical evaluation
of the prognostic factors, such as age, cytogenetic char-
acteristics, chance of achieving complete remission, and
availability of a matched unrelated donor should guide
the treating physician in advising the patient about the
available treatment options. The option of autologous
PB stem cell transplantation may be considered a rea-
sonable alternative for patients lacking a donor.
Mobilized PB stem cells are the preferred stem cell
source for young patients, especially in view of the
more rapid hematopoietic recovery after transplanta-
tion with such stem cells, but BM stem cells may also be
considered for patients over 50 years old. Further devel-
opment of precise prognostic classification systems,
including an accurate cytogenetic/molecular response
evaluation to chemotherapy, is needed to develop a
risk-adapted strategy for individual patients.
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